News for LLY Stock

Lilly declares second-quarter 2025 dividend Scribe Therapeutics to Highlight In Vivo CRISPR-based Genome Editing Data for Duchenne Muscular Dystrophy at ASGCT 2025, in Addition to Joint Presentation with Prevail Therapeutics, a Part of Lilly’s Gene Therapy Division Lilly to participate in Bank of America Securities 2025 Healthcare Conference Lilly reports first-quarter 2025 financial results and highlights pipeline momentum Scribe Achieves Milestone for In Vivo Program in Collaboration with Prevail Therapeutics, a part of Lilly’s Gene Therapy Division, and Announces ASGCT Joint Presentation on Self-Inactivating AAV Technology for Neurological and Neuromuscular Disorders Lilly confirms date and conference call for first-quarter 2025 financial results announcement Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial Kanvas Bio Publishes New Research on its Novel Spectral Imaging Platform, a Transformative Tool for Microbiome Drug Discovery and Development Lilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels LillyDirect platform expands to facilitate access to Alzheimer's disease care Lilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study Lilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis Laekna Announces IND Approval of LAE120 (a Novel USP1 Inhibitor) for Treatment of Advanced Solid Tumors by FDA Lilly to participate in Leerink Partners Global Healthcare Conference Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients Lilly to participate in TD Cowen's 45th Annual Health Care Conference Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years Lilly reports full Q4 2024 financial results and provides 2025 guidance Lilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcement FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program Lilly to participate in J.P. Morgan Healthcare Conference FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial) Lilly's Kisunla™ (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease Lilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt Innovent and Lilly Expand Collaboration Through Agreement on Commercialization Rights for Jaypirca® (pirtobrutinib) in Mainland China Lilly's Omvoh® (mirikizumab) recommended by CHMP for approval in the European Union for adults with moderately to severely active Crohn's disease Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer Phase 3 results for Lilly's Jaypirca® (pirtobrutinib) in covalent BTK inhibitor pre-treated chronic lymphocytic leukemia or small lymphocytic lymphoma to be presented at the 2024 ASH Annual Meeting Lilly announces new $15 billion share repurchase program and seventh consecutive 15% dividend increase CORE Kidney, Boehringer Ingelheim and Lilly Are Turning Up the Volume on Kidney Health at the 2025 Tournament of Roses® Parade Lilly announces $3 billion expansion of its recently acquired manufacturing facility in Wisconsin Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7% Lilly announces changes on board of directors Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks Asha Therapeutics Awarded Barnett Drug Development Grant by the ALS Association to Advance Novel Intra-Molecular Glue Inhibitor of SARM1 to Clinic and Announces Appointment of Disarm Therapeutics’ Founders to Company’s Scientific Advisory Board Lilly announces details of presentations at the 2024 American Society of Hematology (ASH) Annual Meeting Lilly to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer's Disease Patients in Phase 3b study Lilly declares fourth-quarter 2024 dividend Lilly's mirikizumab is first and only IL23p19 antagonist to report long-term, multi-year, sustained efficacy and safety data for both ulcerative colitis and Crohn's disease Lilly's EBGLYSS™ (lebrikizumab-lbkz) demonstrated meaningful improvement in skin clearance and itch relief in the majority of patients with moderate-to-severe atopic dermatitis who discontinued dupilumab Lilly's Kisunla™ (donanemab-azbt) Receives Marketing Authorization in Great Britain for the Treatment of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in Adult Patients Who Are Apolipoprotein E Ε4 Heterozygotes or Non-Carriers Lilly confirms date and conference call for third-quarter 2024 financial results announcement Survey reveals 8 in 10 Americans with ulcerative colitis struggle to find a public restroom during emergencies Lilly reports one-year histologic outcomes in Phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease Lilly announces new $4.5 billion site - the Lilly Medicine Foundry - to drive innovation in drug production and make medicines for clinical trials New data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis Lilly expands manufacturing footprint in Ireland with $1.8 billion investment With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetes Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes Lilly appoints Lucas Montarce as executive vice president and chief financial officer In a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulin Lilly and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countries Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity Lilly to participate in Morgan Stanley 22nd Annual Global Healthcare Conference Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight Lilly announces retirement of Marschall S. Runge from its Board of Directors Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease Lilly opens state-of-the-art research and development center in the Boston Seaport Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity Lilly Confirms Date and Conference Call for Second-Quarter 2024 Financial Results Announcement GordonMD® Global Investments Portfolio Company, Radionetics Oncology, Announced Strategic Agreement with Lilly Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease Lilly collaborates with OpenAI to discover novel medicines to treat drug-resistant bacteria Lilly Declares Third-Quarter 2024 Dividend Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients achieved improvement in fibrosis at 52 weeks Lilly announces departure of Anat Ashkenazi, chief financial officer Melissa Seymour to join Lilly as executive vice president of Global Quality Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting Lilly, UNICEF expand support to help millions of young people at risk of noncommunicable diseases Lilly to Participate in Goldman Sachs 45th Annual Global Healthcare Conference Lilly Increases Manufacturing Investment to $9 Billion at Newest Indiana Site to Boost API Production for Tirzepatide and Pipeline Medicines Lilly Announces Details of Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting More than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved clinical remission at one year, including patients with previous biologic failure With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin Alonzo Weems to Retire as Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance Officer Lilly Declares Second-Quarter 2024 Dividend Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results Announcement More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of Donanemab Lilly's Newest Phase of Get Better Campaign Challenges Misperceptions About Obesity Care Lilly Announces Details of Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting Lilly to Participate in Cowen's 44th Annual Health Care Conference Philip Johnson to Retire as Lilly Treasurer Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance Johna Norton to Retire as Lilly Executive Vice President of Global Quality Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting Lilly Confirms Date and Conference Call for Fourth-Quarter 2023 Financial Results and 2024 Financial Guidance Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect™ Lilly to Participate in J.P. Morgan Healthcare Conference Lilly Completes Acquisition of POINT Biopharma Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023 Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting Lilly's Zepbound™ (tirzepatide) achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over 88 weeks Lilly Announces 15% Dividend Increase, First-Quarter 2024 Dividend Lilly to Present Final Overall Survival Analysis from the MONARCH 3 Study of Verzenio® (abemaciclib) and Additional Results from Its Breast Cancer Portfolio at the 2023 San Antonio Breast Cancer Symposium Zepbound™ (tirzepatide) is Now Available in U.S. Pharmacies for Adults Living with Obesity Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023 Jaypirca® (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor and a BCL-2 Inhibitor Alexandria Real Estate Equities, Inc. Announces Exclusive Partnership With Lilly to Expand Lilly Gateway Labs to San Diego Lilly Announces Plans to Open its First-ever Gateway Labs Site in San Diego Lilly to expand injectable manufacturing capacity with planned $2.5 billion site in Germany Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023 Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma Lilly to Participate in Evercore ISI HealthCONx Conference Lilly Announces Extension of Tender Offer to Acquire POINT Biopharma FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems OrsoBio Announces $60M Series A Financing to Advance Metabolic Portfolio for the Treatment of Obesity and Associated Disorders Lilly Announces Details of Pirtobrutinib Presentations in B-Cell Malignancies at 2023 ASH Annual Meeting Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity Hip-Hop Classic "It Takes Two" Takes on New Meaning in Remix to Elevate Importance of Testing for Kidney Disease Lilly Declares Fourth-Quarter 2023 Dividend FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis Lilly to Participate in UBS Biopharma Conference 2023 Lilly's Retevmo® (selpercatinib) Phase 3 Results in RET Fusion-Positive Non-Small Cell Lung Cancer and RET-Mutant Medullary Thyroid Cancer Both Published in The New England Journal of Medicine and Presented in a Presidential Symposium at ESMO Congress 2023 Lilly Confirms Date and Conference Call for Third-Quarter 2023 Financial Results Announcement Landmark 5-Year monarchE Outcome Data Demonstrate Verzenio® (abemaciclib)'s Long-Term Impact on Cancer Recurrence in High-Risk Early Breast Cancer Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost clear skin with Lilly's lebrikizumab monthly maintenance dosing at two years Lilly's tirzepatide shows additional 21.1% weight loss after 12 weeks of intensive lifestyle intervention, for a total mean weight loss of 26.6% from study entry over 84 weeks Lilly's Mirikizumab Helped Patients with Crohn's Disease Achieve Long-Term Remission in Phase 3 Trial Lilly Announces Details of Presentations at ESMO Congress 2023 Loxo@Lilly Unveils Three New Oncology Programs at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Lilly Announces Leadership Transitions Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies U.S. Food and Drug Administration Issues Complete Response Letter for Lebrikizumab Based on Inspection Findings at Third-Party Manufacturer US FDA approves Jardiance® for the treatment of adults with chronic kidney disease Lilly's Retevmo® (selpercatinib) Demonstrates Superior Progression-Free Survival Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer Lilly Completes Acquisition of Versanis Bio Lilly Completes Acquisition of Sigilon Therapeutics Lilly Completes Acquisition of DICE Therapeutics Lilly Reports Second-Quarter 2023 Financial Results, Highlights Accelerating Revenue Growth and Key Pipeline Advancements Lilly's Retevmo® (selpercatinib) is the First Targeted Therapy to Demonstrate Superior Progression-Free Survival Compared to a PD-1 Inhibitor Plus Chemotherapy for Adults with Newly-Diagnosed Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer Tirzepatide demonstrated significant and superior weight loss compared to placebo in two pivotal studies Lilly Confirms Date and Conference Call for Second-Quarter 2023 Financial Results Announcement Jardiance® (empagliflozin) approved in the EU for the treatment of adults with chronic kidney disease Lilly Announces Extension of Tender Offer to Acquire DICE Results from Lilly's Landmark Phase 3 Trial of Donanemab Presented at Alzheimer's Association Conference and Published in JAMA Medicxi asset-centric portfolio company Versanis Bio to be acquired by Lilly to improve patient outcomes in cardiometabolic diseases Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases Lilly Announces Webcast to Provide Alzheimer's Disease Update at AAIC RemeGen and Innovent Collaborate on Clinical Trials to Evaluate the Potential of RC88 and RC108 Combined with PD-1 Therapy for Advanced Solid Tumors New England Journal of Medicine Publishes BRUIN Phase 1/2 Trial Data for Pirtobrutinib in BTK Inhibitor Pre-Treated Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Lilly to Acquire Sigilon Therapeutics Lilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight Lilly Declares Third-Quarter 2023 Dividend Lilly's SURMOUNT-2 results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes Lilly's phase 2 results published in the New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 weeks in adults with obesity or overweight US FDA approves Jardiance® (empagliflozin) for the treatment of type 2 diabetes in children 10 years and older Lilly to present new research in the treatment of diabetes and obesity at the American Diabetes Association's® 83rd Scientific Sessions Lilly Teams up with the American Diabetes Association and Adam Duvall to Launch "Tap the Cap" Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention Lilly Highlights Verzenio® (abemaciclib) and Jaypirca™ (pirtobrutinib) Data at 2023 ASCO® Annual Meeting Lilly to Participate in Goldman Sachs Global Healthcare Conference Lilly ESG Report Highlights Progress Towards Sustainability Goals Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine Loxo@Lilly Announces Details of Presentations at 2023 European Hematology Association (EHA) Annual Meeting The China NMPA Approves TYVYT® (sintilimab injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-mutated Non-squamous NSCLC who Progressed after EGFR-TKI Therapy Lilly's Social Impact Venture Capital Portfolio Poised to Grow to $300 Million with New $50 Million Allocation Lilly Discloses First-in-Class, Interim Phase 2 Data in Pediatric Patients and New Analysis from Phase 3 Program in Adult Patients for Mirikizumab in Ulcerative Colitis Lilly to Participate in Bank of America Securities 2023 Healthcare Conference Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease Lilly Provides $500,000 in Grants to Support Equitable Access to Education for Dreamers in Indiana Lilly Declares Second-Quarter 2023 Dividend Up to 73% of Atopic Dermatitis Patients Taking Lilly's Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis Lilly Reports First-Quarter 2023 Financial Results, Highlights Continued Core Business Growth and Pipeline Momentum Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2 Lilly to Divest BAQSIMI to Amphastar Lilly to Make Record-Breaking Investment in Indiana Manufacturing Facilities U.S. Food and Drug Administration Issues Complete Response Letter for Mirikizumab Lilly Confirms Date and Conference Call for First-Quarter 2023 Financial Results Announcement Lilly Announces Details of Presentations at 2023 American Association for Cancer Research (AACR) Annual Meeting Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease US FDA accepts supplemental New Drug Application for Jardiance® for children 10 years and older with type 2 diabetes Intensive education at clinics about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines, according to real-world study U.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer Lilly Cuts Insulin Prices by 70% and Caps Patient Insulin Out-of-Pocket Costs at $35 Per Month Lilly to Participate in Cowen's 43rd Annual Health Care Conference Lilly and IABL Collaborate to Ensure Patient Access to High-Quality Affordable Insulin in Bangladesh Lilly to Participate in SVB Securities Global Biopharma Conference Lilly to Participate in Guggenheim Oncology Conference Lilly Reports Fourth-Quarter 2022 Financial Results, Core Business Growth and Pipeline Advancements Support Strong Long-Term Outlook U.S. FDA Approves Jaypirca™ (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma After at Least Two Lines of Systemic Therapy, Including a BTK Inhibitor Lilly Supports Direct Relief's Efforts to Expand Access to Medicines by Improving Cold Chain Capacity Be Nimble Foundation to Source Talent within Lilly's Skills First Program Lilly Plans to Invest Additional $450 million at Manufacturing Site in Research Triangle Park US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease U.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Approval of Donanemab Lilly Confirms Date and Conference Call for Fourth-Quarter 2022 Financial Results Announcement Lilly to Participate in the J.P. Morgan Healthcare Conference Lilly and ProQR to Expand RNA Editing Collaboration Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa Lilly Announces 2023 Financial Guidance, Plans to Launch up to Four New Medicines Loxo@Lilly Presents Updated Pirtobrutinib Data from the Phase 1/2 BRUIN Clinical Trial at the 2022 American Society of Hematology Annual Meeting Lilly Announces 15% Dividend Increase, First-Quarter 2023 Dividend Phase III trial demonstrated Jardiance® is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes Lilly Announces Updated Data from the Verzenio® (abemaciclib) Phase 3 monarchE Trial Presented at SABCS and Simultaneously Published in The Lancet Oncology Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases Lilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptomatic Alzheimer's Disease Lilly and Akouos Announce Expiration of Akouos Tender Offer Lilly Confirms Date and Conference Call for 2023 Financial Guidance Announcement Lilly to Participate in Evercore ISI HealthCONx Conference Lilly to begin rollout of Tempo® Personalized Diabetes Management Platform Bigfoot Biomedical Announces Insulin Compatibility Expansion to Support Insulin Affordability and Flexibility for People with Diabetes Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease Loxo@Lilly Announces Details of Presentations at the 2022 American Society of Hematology Annual Meeting Lilly Reports Solid Third-Quarter 2022 Financial Results and Continued Pipeline Progress Lilly commits $92.5 million to Purdue to establish an innovative pharmaceutical manufacturing scholarship program and to extend research collaboration Lilly Confirms Date and Conference Call for Third-Quarter 2022 Financial Results Announcement Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss Lilly Declares Fourth-Quarter 2022 Dividend Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities FDA Approves Lilly's Retevmo® (selpercatinib), the First and Only RET Inhibitor for Adults with Advanced or Metastatic Solid Tumors with a RET Gene Fusion, Regardless of Type Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly's Phase 3 Monotherapy Atopic Dermatitis Trials Lilly Announces Details of Presentations at ESMO Congress 2022 Lilly to Participate in Morgan Stanley 20th Annual Global Healthcare Conference Lilly to Participate in Citi's 17th Annual BioPharma Conference Lilly Announces Leadership Transition in Human Resources and New Chief Commercial Officer for Loxo@Lilly Lilly's Taltz® (ixekizumab) Now Available in New, Citrate-Free Formulation to Reduce Injection Site Pain for Improved Patient Experience Lilly Updates Conference Call Start Time for Second-Quarter 2022 Financial Results Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines and Pipeline Advancements Lilly Confirms Date and Conference Call for Second-Quarter 2022 Financial Results Announcement Lilly will supply an additional 150,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options Lilly Declares Third-Quarter 2022 Dividend FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trials New analyses of Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes presented at the American Diabetes Association's® 82nd Scientific Sessions® Jardiance® decreased relative risk of hospitalization for heart failure by 50% versus DPP-4 inhibitors and by 30% versus GLP-1 receptor agonists in adults with type 2 diabetes in real-world evidence study Lilly's AWARD-PEDS trial investigating use of Trulicity® (dulaglutide) in youth and adolescents with type 2 diabetes showed superiority in A1C reduction vs placebo Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight Lilly to Participate in Goldman Sachs Global Healthcare Conference Lilly Announces Details of Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Bigfoot Biomedical® Strengthens Leadership Team with Experienced Chief Commercial Officer Lilly plans to invest $2.1 billion in new manufacturing sites in Indiana Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study Lilly Announces Webcast to Provide Diabetes and Obesity Portfolio Update at ADA CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA) Lilly to Participate in UBS Global Healthcare Conference 2022 FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19 Mary Lynne Hedley Elected to Lilly Board of Directors Lilly to Participate in Bank of America Securities 2022 Healthcare Conference Lilly Declares Second-Quarter 2022 Dividend IgGenix Announces Move of Headquarters to Lilly Gateway Labs in South San Francisco Solid First-Quarter Financial Results Reflect Lilly's Continued Momentum into 2022 Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1 Tackling Health Disparities and Inequities for Women with Heart Failure: New Program Encourages Black and Latina Women to Demand More From Their Care Lilly Confirms Date and Conference Call for First-Quarter 2022 Financial Results Announcement Lilly's Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis Lilly Presents Updated Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer (NSCLC) at the 2022 European Lung Cancer Congress Innovent and Lilly Expand Strategic Partnership in Oncology Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly's Pivotal Phase 3 Atopic Dermatitis Studies Lilly Announces Complete Response Letter for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer Jardiance® phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease Lilly Announces Details of Presentations at 2022 American Association for Cancer Research (AACR) Lilly to Participate in Barclays Global Healthcare Conference Jardiance® provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE phase III trial Lilly to Participate in Cowen Health Care Conference US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction Lilly Announces the Institute for Genetic Medicine and $700 Million investment in Boston Seaport Site Nearly Two-Thirds of Patients Respond to Mirikizumab Treatment at 12 Weeks in Lilly's First-in-Class Ulcerative Colitis Phase 3 LUCENT-1 Study Lilly and Breast Cancer Advocacy Organizations Collaborate to Drive Awareness of the Complexities of Early Breast Cancer and the Risk of Recurrence Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19 Lilly will supply up to 600,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options Cynthia Cardona Elected as President of the Lilly Foundation Lilly Reports Solid Fourth-Quarter and Full-Year 2021 Financial Results, Recent Late-Stage Pipeline Successes Set Up Next Wave of Innovative Medicines for Patients UNICEF and Lilly Collaborate to Help Improve Health Outcomes for 10 Million Children and Adolescents Lilly to Participate in Guggenheim Oncology Conference Eagle Pharmaceuticals Announces Commercial Availability of PEMFEXY™ Lilly announces $1 billion investment in new manufacturing facility in North Carolina Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis Lilly Confirms Date and Conference Call for Fourth-Quarter and Full-Year 2021 Financial Results Announcement Lilly to Participate in the J.P. Morgan Healthcare Conference Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications Lilly's lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study Lilly Highlights Innovation-based Growth Strategy and Pipeline Developments; Announces 2022 Financial Guidance at Investment Community Meeting Mirikizumab Demonstrates Superiority over Placebo in Phase 3 Maintenance Study in Ulcerative Colitis, Supporting Regulatory Submissions in 2022 Lilly Announces 15 Percent Dividend Increase, First-Quarter 2022 Dividend Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for Pirtobrutinib at the American Society of Hematology Annual Meeting Lilly and Regor Therapeutics Group Enter into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic Disorders New Lilly Study Reveals Underappreciation of Bowel Urgency as a Symptom of Ulcerative Colitis and Highlights Communication Gap Between Healthcare Providers and Patients Lilly's bamlanivimab with etesevimab authorized as the first and only neutralizing antibody therapy for emergency use in COVID-19 patients under the age of 12 Lilly to Announce Initial 2022 Financial Guidance; Provide R&D Overview at Investment Community Meeting Emgality® Versus Nurtec® ODT Head-to-Head Migraine Preventive Treatment Study Now Enrolling Patients Lilly to Participate in Fourth Annual Evercore ISI HealthCONx Conference US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction Lilly announces winners of inaugural Leonard Award, a global program celebrating 100 years of innovation in diabetes care Lilly to Participate in Wolfe Research Virtual Healthcare Conference OLUMIANT® Long-Term Safety Profile Established Up to 9.3 Years in Integrated Analysis of More Than 3,700 Patients with Rheumatoid Arthritis Jardiance® shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40% regardless of chronic kidney disease status Loxo Oncology at Lilly Announces Details of Presentations at the 2021 American Society of Hematology (ASH) Annual Meeting Lilly to supply 614,000 additional doses of bamlanivimab and etesevimab to the U.S. Government for the treatment or post-exposure prevention of COVID-19 Lilly to Participate in Bernstein's Second Annual Operational Decisions Conference Additional Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Published in the Annals of Oncology Lilly Reports Robust Third-Quarter 2021 Financial Results as Pipeline Success Strengthens Future Growth Potential Tirzepatide results published in The Lancet show superior A1C and body weight reductions compared to insulin glargine in adults with type 2 diabetes with increased cardiovascular risk Lilly Declares Fourth-Quarter 2021 Dividend Lilly Announces Updated Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Presented at ESMO Virtual Plenary and Simultaneously Published in the Annals of Oncology FDA Approves Verzenio® (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer Lilly Confirms Date and Conference Call for Third-Quarter 2021 Financial Results Announcement Loxo Oncology at Lilly Announces Details of Presentations at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals At Week 104, 75% of Patients with Ulcerative Colitis Taking Mirikizumab Maintained Symptomatic Remission in Phase 2 Study OLUMIANT® Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata Lilly's tirzepatide led to greater improvements in liver fat content compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 MRI sub-study Lilly's tirzepatide led to greater time in range compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 CGM sub-study Lilly and Susan G. Komen® Partner to Address Disparities in Breast Cancer Outcomes Experienced By Black Women FDA Expands Lilly's ERBITUX® (cetuximab) Label with Combination of BRAFTOVI® (encorafenib) for the Treatment of BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) after Prior Therapy Lilly again reduces list price of Insulin Lispro Injection as latest change to affordability options New Data from Verzenio® (abemaciclib) monarchE Study to Be Featured in ESMO Virtual Plenary Eli Lilly and Company Issues Voluntary Nationwide Recall of One Lot of GLUCAGON® Emergency Kit Due to Loss of Potency Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities Lilly announces procurement agreement with European Commission to supply bamlanivimab and etesevimab together for the treatment of confirmed COVID-19 Lilly Announces the Early Tender Results of Its Pending Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities and Removal of the Note Caps for Its 3.950% Notes due 2049 and Its 4.150% Notes due 2059 Emergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19 Lilly to supply 388,000 doses of etesevimab to U.S. government for treatment of COVID-19 Lilly to Participate in the 2021 Cantor Virtual Global Healthcare Conference Lilly to Present New Data from Oncology Portfolio at ESMO Congress Lilly Prices First Sustainability Bond to Advance Global ESG Strategy FDA grants Jardiance® Breakthrough Therapy designation for heart failure with preserved ejection fraction Lilly Diabetes joins The Leona M. and Harry B. Helmsley Charitable Trust to pledge significant funding to "Type 1 Diabetes Camps Initiative" Lilly Announces Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities Lilly to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference Lilly to Participate in Citi's 16th Annual BioPharma Virtual Conference Lilly Announces that Professor Carolyn Bertozzi has Resigned from its Board of Directors Lilly and Lycia Therapeutics Enter into Strategic Collaboration to Discover and Develop Novel Lysosomal Targeting Chimera (LYTAC) Degraders US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units FDA approves Lyumjev® (insulin lispro-aabc injection) 100 units/mL for use in insulin pumps Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials Lilly Delivers Strong Second-Quarter 2021 Financial Results, Updates 2021 Financial Guidance Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation Lilly releases donanemab data that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive decline FDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygen Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses Lilly Confirms Date and Conference Call for Second-Quarter 2021 Financial Results Announcement Lilly and Incyte provide update on supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis Lilly and Banner Alzheimer's Institute collaborate on planned Phase 3 prevention trial of donanemab Lilly Announces Acquisition of Protomer Technologies Mirikizumab Up-Regulates Genes Associated with Mucosal Healing in Ulcerative Colitis for Up to One Year in Phase 2 Study Breakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction Lilly Declares Third-Quarter 2021 Dividend Lilly's SURPASS-1 results published in The Lancet show tirzepatide's superior A1C and body weight reductions versus placebo in adults with type 2 diabetes Lilly's SURPASS-2 results published in The New England Journal of Medicine show tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type 2 diabetes Lilly announces call for Leonard Award nominations as part of global initiative celebrating 100 years of insulin Lilly's donanemab receives U.S. FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease Lilly Launches Think Talk Treat Migraine™ to Help Improve Diagnosis and Treatment of Migraine Lilly Announces Head-to-Head Study Comparing Once-Monthly Emgality® with Every-Other-Day Nurtec® ODT for the Preventive Treatment of Migraine Lilly to Participate in Guggenheim Biopharma Strategy Series Lilly Announces Webcast to Provide Diabetes Portfolio Update at ADA Lilly Announces New Clinical Data from Verzenio and Oral SERD Programs at the American Society of Clinical Oncology Annual Meeting Lilly to Participate in Goldman Sachs Healthcare Conference Lilly Reveals Critical Barriers to Optimal Migraine Care and Insights From Novel Clinical and Patient-Centric Real-World Evidence, Supporting Lilly's Preventive and Acute Treatment Portfolio at AHS 2021 OLUMIANT® Improved Pain, Physical Function and Morning Joint Stiffness in Rheumatoid Arthritis in Phase 3 Post-Hoc Analyses Taltz® Showed Consistent, Long-Term Improvement in Key Signs and Symptoms of Axial Spondyloarthritis Through Two Years in Phase 3 Study Mirikizumab Improves Fatigue in Patients with Crohn's Disease in Phase 2 Trial Lilly's tirzepatide achieves all primary and key secondary study outcomes against insulin glargine in adults with type 2 diabetes and increased cardiovascular risk in SURPASS-4 trial Lilly Announces Details of Presentations at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting U.S. FDA Accepts Regulatory Submission for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer Lilly to Participate in UBS Global Healthcare Virtual Conference Lilly and MiNA Therapeutics Announce saRNA Research Collaboration Lilly collaborates internationally with leading diabetes technology companies to integrate connected insulin pen solutions for people with diabetes Lilly to Participate in Bank of America Securities 2021 Health Care Conference Lilly plans donation of COVID-19 therapies to Direct Relief for use in low- and lower-middle-income countries Lilly Outlines Robust Plans to Strengthen ESG Commitments Across the Globe Lilly accelerating baricitinib's availability in India following receipt of permission for restricted emergency use as a COVID-19 therapy via donations and licensing agreements Lilly Declares Second-Quarter 2021 Dividend and Announces Additional Share Repurchase Authorization Lilly to Commit $5 Million to Direct Relief's Fund for Health Equity Lilly Delivers First-Quarter 2021 Financial Results, Adjusts 2021 Financial Guidance Taltz® Delivers More Cumulative Days with Completely Clear Skin for Adults with Psoriasis Compared to Seven Other Biologics in Novel Network Meta-Analysis OLUMIANT® Showed Significant Improvements in the Severity and Extent of Atopic Dermatitis and Other Patient-Reported Outcomes in Phase 3 Study Analyses Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study Lilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S. Diogo Rau to join Lilly as Senior Vice-President and Chief Information and Digital Officer Lilly modified COVID-19 purchase agreement for bamlanivimab alone with the U.S. government and is focusing on supply of bamlanivimab and etesevimab together Lilly Presents New Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Gastrointestinal and Other Cancers at 2021 American Association for Cancer Research (AACR) Annual Meeting Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients Lilly and Incyte communicate review extension of supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis Lilly Confirms Date and Conference Call for First-Quarter 2021 Financial Results Announcement Lilly to Host Sustainability Webcast to Provide Overview of Environmental, Social and Governance (ESG) Efforts Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19 Innovent and Lilly Jointly Announce Results of Six Clinical Studies of TYVYT® (sintilimab injection) to be Presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 Lilly Presents Patient-Reported Outcomes from the Positive Phase 3 monarchE Trial for Verzenio® at St. Gallen Virtual Congress 2021 Lilly's Mirikizumab Helps Patients Achieve Clinical Remission and Improves Symptoms in Adults with Ulcerative Colitis in 12-Week Phase 3 Induction Study Lilly's donanemab slowed Alzheimer's disease progression in Phase 2 trial: full data presented at AD/PD™ 2021 and published in NEJM Lilly Announces Details of Presentations at 2021 American Association for Cancer Research (AACR) Lilly's bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19 Data from Lilly at International Conference on Alzheimer's & Parkinson Diseases 2021™ (AD/PD™ 2021) to Showcase Clinical Advances in Alzheimer's Disease Research Lilly Announces Leadership Transitions in Manufacturing and Ethics and Compliance Organizations Lilly and Biolojic Design Announce Research Collaboration to Discover and Develop Antibody Therapies for Diabetes Lilly to Participate in Barclays Global Healthcare Conference EMA issues advice on Lilly's bamlanivimab (LY-CoV555) alone and administered together with etesevimab (LY-CoV016) for the treatment of confirmed COVID-19 in the European Union Loxo Oncology at Lilly Announces Publication of Pirtobrutinib (LOXO-305) Phase 1/2 Data in The Lancet Tirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetes Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial Lilly announces additional doses of neutralizing antibody therapy purchased by U.S. government to treat COVID-19 Welldoc and Lilly collaborate to integrate BlueStar® app capabilities into Lilly's connected insulin solutions Lilly to Participate in Cowen Health Care Conference Lilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative Diseases Tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly's SURPASS program Kimberly H. Johnson Elected to Lilly Board of Directors Lilly To Participate in SVB Leerink Global Healthcare Conference Lilly's bamlanivimab (LY-CoV555) administered with etesevimab (LY-CoV016) receives FDA emergency use authorization for COVID-19 Lilly Appoints Anat Ashkenazi Chief Financial Officer Lilly Announces Webcast to Provide Alzheimer's Disease Update at AD/PD Conference Lilly to Participate in Guggenheim Healthcare Talks 2021 Oncology Day Lilly Partners with Area Health Systems to Help Enable Access to Important Antibody Infusion Therapies for COVID-19 Patients Lilly Reports Strong Fourth-Quarter and Full-Year 2020 Financial Results Lilly, Life for a Child and Beyond Type 1 advance partnership to improve diabetes care in resource-limited countries Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19 New data show treatment with Lilly's neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together reduced risk of COVID-19 hospitalizations and death by 70 percent Lilly Completes Acquisition of Prevail Therapeutics Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies Lilly Confirms Date and Conference Call for Fourth-Quarter 2020 Financial Results Announcement Lilly Announces $30 Million Limited Partner Investment in Unseen Capital Health Fund Gabrielle Sulzberger Elected to Lilly Board of Directors US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction Lilly's Donanemab Slows Clinical Decline of Alzheimer's Disease in Positive Phase 2 Trial Lilly to Participate in J.P. Morgan Healthcare Conference Principle LTC's Tower Nursing & Rehabilitation Center Joins with Eli Lilly and Company on Phase 3 Drug Trial for COVID-19 Prevention Lilly to begin pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19 in New Mexico Lilly Announces 2021 Financial Guidance, Updates 2020 Guidance Lilly Announces 15 Percent Dividend Increase Lilly announces opening of patient enrollment for New IDEAS: Imaging Dementia - Evidence for Amyloid Scanning study Data from ACTT-2 Trial of Baricitinib in Hospitalized COVID-19 Patients Supportive of the EUA Published in New England Journal of Medicine Lilly Presents Positive Primary Outcome Data from monarchE that Builds on Previous Definitive Analysis for Verzenio® Lilly's tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes Lilly Confirms Date and Conference Call for 2021 Financial Guidance Announcement Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at the American Society of Hematology Annual Meeting Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Mantle Cell Lymphoma and Non-Hodgkin Lymphomas at the American Society of Hematology (ASH) Annual Meeting Lilly announces 650,000 additional doses of neutralizing antibody bamlanivimab (LY-CoV555) purchased by U.S. government to treat COVID-19 Lilly to Participate in Evercore ISI 3rd Annual HealthCONx Conference Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives interim authorization from Health Canada as a treatment for COVID-19 Baricitinib Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19 Lilly and Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes Jardiance® reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial Lilly to Participate in Wolfe Research Virtual Healthcare Conference Lilly to Participate in Bernstein Operational Decisions Conference Lilly Announces Webcast to Provide an Overview of Tirzepatide Phase 3 clinical program Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives FDA emergency use authorization for the treatment of recently diagnosed COVID-19 Loxo Oncology at Lilly Announces Details of LOXO-305 Presentations at the 2020 American Society of Hematology (ASH) Annual Meeting Aarti Shah to Retire as Lilly Chief Information and Digital Officer ACR 2020: Lilly and Incyte Highlight Positive Data for Olumiant® in Rheumatoid Arthritis EADV 2020: Lilly and Incyte Showcase New Data for Baricitinib for the Treatment of Moderate to Severe Atopic Dermatitis Fall Clinical Dermatology 2020: Lilly and Incyte Showcase Positive New Data for Baricitinib in Adult Patients with Alopecia Areata New Data at EADV 2020 Confirm Taltz® (ixekizumab) Demonstrates Sustained Long-Term Efficacy in Patients with Psoriasis and Psoriatic Arthritis Data for Lilly's bamlanivimab (LY-CoV555) in COVID-19 outpatients published in New England Journal of Medicine Lilly announces agreement with U.S. government to supply 300,000 vials of investigational neutralizing antibody bamlanivimab (LY-CoV555) in an effort to fight COVID-19 Lilly Reports Third-Quarter Financial Results, Updates Guidance New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status Lilly Declares Fourth-Quarter 2020 Dividend Lilly Announces Agreement to Acquire Disarm Therapeutics Mirikizumab Shows Continued Symptom Improvement and Reduction of Intestinal Inflammation in Patients with Crohn's Disease in 52-Week Phase 2 Trial Lilly's OVERCOME Study Reveals Nearly 80% of People Reported Improvement in Their Migraine Since Starting a CGRP Monoclonal Antibody for Preventive Treatment Lilly Confirms Date and Conference Call for Third-Quarter 2020 Financial Results Announcement Baricitinib has Significant Effect on Recovery Time, Most Impactful in COVID-19 Patients Requiring Oxygen Lilly Announces Arrangement for Supply of Potential COVID-19 Antibody Therapy for Low- and Middle-Income Countries Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs REYVOW® (lasmiditan) C-V Demonstrated Superior Pain Freedom At 2 Hours in At Least 2 of 3 Migraine Attacks in New Phase 3 Consistency of Effect Study Trulicity® (dulaglutide) is now indicated as an adjunct to diet, exercise, and standard of care therapy to reduce the risk of non-fatal stroke in adults with type 2 diabetes mellitus who have multiple cardiovascular risk factors or established cardiovascul Verzenio® Significantly Reduced the Risk of Cancer Recurrence by 25% for People with HR+, HER2- High Risk Early Breast Cancer CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting Lilly Launches Digital Health Open Innovation Challenge to Help Transform Atopic Dermatitis Care US FDA grants Fast Track designation to Jardiance® (empagliflozin) to improve outcomes following a heart attack Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial Innovent and Lilly Jointly Announce Results of Six Clinical Studies of TYVYT® (sintilimab injection) to be Presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 Lilly to Participate in Cantor Fitzgerald Virtual Global Healthcare Conference Lilly to Participate in Morgan Stanley Global Healthcare Conference REYVOW™ (lasmiditan) C-V Demonstrated Pain Freedom from Migraine Attacks At 60 Minutes and Up to 48 Hours in New Phase 3 Study Lilly Announces Webcast to Discuss ESMO 2020 Presentations Lilly commits Insulin Value Program, featuring $35 copay card, to suite of affordability solutions for people with diabetes Lilly Oncology to Showcase New Data from Robust Cancer Research Pipeline at ESMO Virtual Congress 2020 Lilly Announces Leadership Changes FDA approves additional doses of Trulicity® (dulaglutide) for the treatment of type 2 diabetes Jardiance® reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25% in adults with and without diabetes who had heart failure with reduced ejection fraction New England Journal of Medicine Publishes Phase 1/2 Data for Retevmo™ (selpercatinib) in Advanced RET-Driven Lung and Thyroid Cancers Lilly and Innovent Announce Global Expansion of TYVYT Licensing Agreement FDA approves Lyumjev™ (insulin lispro-aabc injection), Lilly's new rapid-acting insulin Once-weekly Trulicity® (dulaglutide) demonstrates significantly higher adherence and more persistence compared to once-weekly semaglutide and exenatide injections Lilly Initiates Phase 3 Trial of LY-CoV555 for Prevention of COVID-19 at Long-Term Care Facilities in Partnership with the National Institute of Allergy and Infectious Diseases (NIAID) Jardiance® meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in phase III trial in adults with and without diabetes Data from Lilly at Alzheimer's Association International Conference 2020® (AAIC® 2020) to Showcase Clinical Advances in Alzheimer's Research Lilly's Mirikizumab Superior to Cosentyx® (secukinumab) in a Phase 3 Study for Patients with Moderate to Severe Plaque Psoriasis Lilly launches program about what people with diabetes should "Know Before the Low™" Emgality® Demonstrates Reduction in Frequency, Duration, and Pain Severity in Patients with Episodic and Chronic Migraine Verzenio® (abemaciclib) Significantly Reduced the Risk of Cancer Returning in People with High Risk HR+, HER2- Early Breast Cancer Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients Lilly Reports Second-Quarter Financial Results, Raises EPS Guidance Lilly's P-tau217 Blood Test Shows High Accuracy in Diagnosis of Alzheimer's Disease in Data Published in JAMA Lilly Confirms Date and Conference Call for Second-Quarter 2020 Financial Results Announcement Lilly Declares Third-Quarter 2020 Dividend Full results from EMPERIAL exercise ability trials presented Lilly's OVERCOME Study Reveals Less than 30 Percent of People Living with Migraine Take Recommended Prescription Medications